Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

RAD402

Radiopharmaceutical · developed by Radiopharm Theranostics

Phase 1/2 Most advanced trial
RADX Developer
1 Registered trials

What is RAD402?

161Tb RAD402 is a radiopharmaceutical labeled with the radioisotope terbium-161.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Therapy area
Oncology
Developer
Radiopharm Theranostics, Ltd (RADX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07259213 Phase 1/2 Castration-resistant Prostate Cancer Recruiting RADX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Castration-resistant Prostate Cancer

More from Radiopharm Theranostics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RADX page.

Follow RADX, the company behind RAD402

See RADX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RADX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.